Fig. 6: Humanized anti-Vβ2 therapeutic antibody with enhanced ADCC.
From: Generation and optimization of off-the-shelf immunotherapeutics targeting TCR-Vβ2+ T cell malignancy
a An anti-Vβ2 antibody competition assay, in which 1.25μg/ml mouse anti-Vβ2-FITC antibody was mixed with varying concentrations of humanized anti-Vβ2-PE antibody and used to stain CTCL cells from a Vβ2+ patient, with Vβ2 MFI determined by flow cytometry. b ADCC assay luminescence signal after a 6 h co-culture of patient derived Vβ2+ target CTCL cells and Jurkat-NFAT-luciferase effector cells mixed with either 100 ng/ml mouse anti-Vβ2 antibody (black) or humanized anti-Vβ2 antibody (red). PBMC from Vβ2+ CTCL patient 1 (c–e) or from Vβ2+ CTCL patient 2 (f–h) were cultured overnight with NK effector cells from a healthy donor at different E:T ratios without antibody addition (black) or with addition of mouse anti-Vβ2 antibody (blue) or humanized anti-Vβ2 antibody (red), then live CTCL cells (c–f) Vβ2- normal T cells (d–g) and non-T cell PBMC (e–h) counts were determined by flow cytometry. c–h N = 3 replicates in each group. Data are presented as mean values +/− SEM. ***p < 0.001 and ****p < 0.0001 by two-way ANOVA. All replicates are independent samples. Source data and exact p-values are provided as a Source Data file.
